{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:39:56Z","timestamp":1786718396971,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Indian Acad Neurol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/aian.aian_97_17","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T07:38:19Z","timestamp":1508917099000},"page":"341","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of tacrolimus in myasthenia gravis: A systematic review and meta-analysis"],"prefix":"10.4103","volume":"20","author":[{"given":"Lingli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiusha","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0972-2327.217182-1","first-page":"1797","volume-title":"Myasthenia gravis","author":"Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0972-2327.217182-2","first-page":"2122","volume-title":"Myasthenia gravis","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"key-10.4103\/0972-2327.217182-3","doi-asserted-by":"crossref","unstructured":"Hohlfeld R, Melms A, Schneider C. Therapy of Myasthenia Gravis and Myasthenic Syndromes. Ch. 94. Neurological Disorders, 2003:1341-62.","DOI":"10.1016\/B978-012125831-3\/50289-6"},{"key":"key-10.4103\/0972-2327.217182-4","first-page":"691","volume-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","author":"Skeie","year":"2006","journal-title":"Eur J Neurol"},{"key":"key-10.4103\/0972-2327.217182-5","first-page":"191","volume-title":"A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids","author":"van","year":"2005","journal-title":"QJM"},{"key":"key-10.4103\/0972-2327.217182-6","doi-asserted-by":"crossref","unstructured":"Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-55.","DOI":"10.7164\/antibiotics.40.1249"},{"key":"key-10.4103\/0972-2327.217182-7","first-page":"803","volume-title":"Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A","author":"Flanagan","year":"1991","journal-title":"Nature"},{"key":"key-10.4103\/0972-2327.217182-8","first-page":"423","volume-title":"European FK506 Multicentre Liver Study Group","author":"Randomised","year":"1994","journal-title":"Lancet"},{"key":"key-10.4103\/0972-2327.217182-9","first-page":"245","volume-title":"Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells","author":"Utsugisawa","year":"2003","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/0972-2327.217182-10","first-page":"146","volume-title":"Effi cacy of low-dose FK506 in the treatment of myasthenia gravis \u2013 A randomized pilot study","author":"Nagane","year":"2005","journal-title":"Eur Neurol"},{"key":"key-10.4103\/0972-2327.217182-11","first-page":"59","volume-title":"Simultaneous and sustained remission of intractable myasthenia gravis and focal segmental glomerulosclerosis with tacrolimus treatment","author":"Chung","year":"2008","journal-title":"Clin Nephrol"},{"key":"key-10.4103\/0972-2327.217182-12","first-page":"970","volume-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","author":"Yoshikawa","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/0972-2327.217182-13","first-page":"108","volume-title":"Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis","author":"Furukawa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"key-10.4103\/0972-2327.217182-14","first-page":"92","volume-title":"The emerging role of tacrolimus in myasthenia gravis","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"key-10.4103\/0972-2327.217182-15","first-page":"16","volume-title":"Myasthenia gravis: Recommendations for clinical research standards.Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"key-10.4103\/0972-2327.217182-16","first-page":"1487","volume-title":"Myasthenia gravis activities of daily living profile","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"key-10.4103\/0972-2327.217182-17","unstructured":"Ponseti JM. Miastenia Gravis. Manual Terap\u00e9utico. Berlin: Springer Verlag Ib\u00e9rica; 1994."},{"key":"key-10.4103\/0972-2327.217182-18","first-page":"87","volume-title":"Myasthenia gravis patients clinical absolute evaluation method and relative evaluation method","author":"Wang","year":"1997","journal-title":"Chin Neurosci J"},{"key":"key-10.4103\/0972-2327.217182-19","unstructured":"Higgins JP, Green S(editor). Cochrane Handbook for Systematic Reviews of Interventions. Ver. 5.1.0. Chichester: The Cochrane Collaboration; 2011. Available from: http:\/\/www.cochrane-handbook.org. [Last updated on 2011 Mar 11]."},{"key":"key-10.4103\/0972-2327.217182-20","first-page":"885","volume-title":"Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis","author":"Ponseti","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/0972-2327.217182-21","first-page":"1641","volume-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"key-10.4103\/0972-2327.217182-22","first-page":"187","volume-title":"Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: One-year follow-up of an open-label study","author":"Ponseti","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"key-10.4103\/0972-2327.217182-23","first-page":"570","volume-title":"Clinical study of FK506 in patients with myasthenia gravis","author":"Konishi","year":"2003","journal-title":"Muscle Nerve"},{"key":"key-10.4103\/0972-2327.217182-24","first-page":"1269","volume-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","author":"Kawaguchi","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/0972-2327.217182-25","first-page":"448","volume-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","author":"Konishi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/0972-2327.217182-26","first-page":"406","volume-title":"Small dose of tacrolimus for the treatment of refractory systemic type myasthenia gravis preliminary study","author":"Zhao","year":"2005","journal-title":"J Clin Neurosci China"},{"key":"key-10.4103\/0972-2327.217182-27","first-page":"17","volume-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis","author":"Tada","year":"2006","journal-title":"J Neurol Sci"},{"key":"key-10.4103\/0972-2327.217182-28","first-page":"519","volume-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"key-10.4103\/0972-2327.217182-29","first-page":"160","volume-title":"Tacrolimus refractory myasthenia gravis treatment efficacy and safety study","author":"Wang","year":"2014","journal-title":"J Pract Med China"},{"key":"key-10.4103\/0972-2327.217182-30","first-page":"100","volume-title":"82 cases of tacrolimus in the treatment of refractory myasthenia gravis feasibility analysis","author":"Chen","year":"2015","journal-title":"China Disabled Med"},{"key":"key-10.4103\/0972-2327.217182-31","first-page":"5","volume-title":"Tacrolimus hydrate (FK506): Therapeutic effects and selection of responders in the treatment of myasthenia gravis","author":"Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"key-10.4103\/0972-2327.217182-32","first-page":"83","volume-title":"Beneficial effect of tacrolimus on myasthenia gravis with thymoma","author":"Mitsui","year":"2007","journal-title":"Neurologist"},{"key":"key-10.4103\/0972-2327.217182-33","first-page":"39","volume-title":"Tacrolimus in refractory patients with myasthenia gravis: Coadministration and tapering of oral prednisolone","author":"Shimojima","year":"2006","journal-title":"J Clin Neurosci"},{"key":"key-10.4103\/0972-2327.217182-34","first-page":"154","volume-title":"Small dose of tacrolimus in the treatment of refractory myasthenia gravis patients clinical analysis","author":"Huei","year":"2015","journal-title":"China Med Guide"},{"key":"key-10.4103\/0972-2327.217182-35","first-page":"1004","volume-title":"Tacrolimus treatment the curative effect of slow metabolism type myasthenia gravis","author":"Pei","year":"2012","journal-title":"Guangdong Med"},{"key":"key-10.4103\/0972-2327.217182-36","first-page":"420","volume-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","author":"Curtis","year":"2006","journal-title":"Arthritis Care Res"},{"key":"key-10.4103\/0972-2327.217182-37","first-page":"11","volume-title":"FK506 prevents induction of rat experimental autoimmune myasthenia gravis","author":"Yoshikawa","year":"1997","journal-title":"J Autoimmun"},{"key":"key-10.4103\/0972-2327.217182-38","first-page":"317","volume-title":"Steroids and immunosuppressant drugs in myasthenia gravis","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"key-10.4103\/0972-2327.217182-39","first-page":"758","volume-title":"A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase","author":"Harding","year":"1989","journal-title":"Nature"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:34:42Z","timestamp":1786714482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_97_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"alternative-id":["217182"],"URL":"https:\/\/doi.org\/10.4103\/aian.aian_97_17","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}